These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 15983299)

  • 41. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
    Dailey GE; Mohideen P; Fiedorek FT
    Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thiazolidinediones: comparison of long-term effects on glycemic control and cardiovascular risk factors.
    Gegick CG; Altheimer MD
    Curr Med Res Opin; 2004 Jun; 20(6):919-30. PubMed ID: 15200751
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lipoprotein effects of different thiazolidinediones in clinical practice.
    Ovalle F; Bell DS
    Endocr Pract; 2002; 8(6):406-10. PubMed ID: 15251829
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
    Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
    Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
    Kutoh E
    Postgrad Med; 2011 Jan; 123(1):45-52. PubMed ID: 21293083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.
    Rosenstock J; Truitt KE; Baz-Hecht M; Ford DM; Tao B; Chou HS
    Horm Metab Res; 2014 Dec; 46(13):943-9. PubMed ID: 25054436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.
    Pavo I; Jermendy G; Varkonyi TT; Kerenyi Z; Gyimesi A; Shoustov S; Shestakova M; Herz M; Johns D; Schluchter BJ; Festa A; Tan MH
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1637-45. PubMed ID: 12679450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids.
    Brackenridge AL; Jackson N; Jefferson W; Stolinski M; Shojaee-Moradie F; Hovorka R; Umpleby AM; Russell-Jones D
    Diabet Med; 2009 May; 26(5):532-9. PubMed ID: 19646194
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.
    Charbonnel BH; Matthews DR; Schernthaner G; Hanefeld M; Brunetti P;
    Diabet Med; 2005 Apr; 22(4):399-405. PubMed ID: 15787663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100 U/mL.
    Hanefeld M; Traylor L; Gao L; Landgraf W
    Cardiovasc Diabetol; 2017 May; 16(1):66. PubMed ID: 28526014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.
    Rosenstock J; Einhorn D; Hershon K; Glazer NB; Yu S;
    Int J Clin Pract; 2002 May; 56(4):251-7. PubMed ID: 12074206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
    Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
    Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of gemfibrozil on lipid profile and glucose metabolism in hypertriglyceridaemic well-controlled non-insulin-dependent diabetic patients. For the Gemfibrozil Study Group.
    Avogaro A; Piliego T; Catapano A; Miola M; Tiengo A
    Acta Diabetol; 1999 Jun; 36(1-2):27-33. PubMed ID: 10436249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].
    Haberbosch W
    Herz; 2007 Feb; 32(1):51-7. PubMed ID: 17323035
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy.
    Derosa G; Tritto I; Romano D; D'Angelo A; Catena G; Maffioli P
    J Clin Pharmacol; 2019 Oct; 59(10):1391-1399. PubMed ID: 31131461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus.
    Chogtu B; Singh NP; Chawla S; Gupta U
    Singapore Med J; 2009 Apr; 50(4):395-9. PubMed ID: 19421684
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of metformin and rosiglitazone on lipid metabolism in HIV infected patients receiving protease inhibitor containing HAART.
    Tomazic J; Karner P; Vidmar L; Maticic M; Sharma PM; Janez A
    Acta Dermatovenerol Alp Pannonica Adriat; 2005 Sep; 14(3):99-105. PubMed ID: 16200335
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US.
    Tunis SL; Minshall ME; St Charles M; Pandya BJ; Baran RW
    Curr Med Res Opin; 2008 Nov; 24(11):3085-96. PubMed ID: 18826750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.